Evolution of congenital haemophilia care in Taiwan.

Autor:	Chen YC; Division of Hematology/Oncology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan. Electronic address: yeuchin99@gmail.com., Chang CY; Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Hemophilia Center, Division of Pediatric Hematology/Oncology, Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan., Cheng SN; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan; Tungs' Taichung MetroHarbor Hospital, Department of Pediatrics, Taichung, Taiwan., Pan RY; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan; Department of Orthopedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan., Shih YL; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan., Li TY; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan; Department of Rehabilitation, Tri-Service General Hospital, National Defence Medical Center, Taipei, Taiwan., Wang SH; Hemophilia Care and Research Center, Tri-Service General Hospital, Taipei, Taiwan; Department of Orthopedics, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
Jazyk:	angličtina
Zdroj:	Journal of the Formosan Medical Association = Taiwan yi zhi [J Formos Med Assoc] 2022 Mar; Vol. 121 (3), pp. 582-591. Date of Electronic Publication: 2021 Aug 03.
DOI:	10.1016/j.jfma.2021.07.017
Abstrakt:	Haemophilia care in Taiwan has come a long way over the past 35 years, from the absence of specialised haemophilia treatment centres before 1984 to the establishment of treatment centers in the majority of medical centers, the listing of haemophilia as a catastrophic illness with full treatment reimbursement by the Taiwan National Health Insurance (NHI), and the implementation of full NHI coverage for prophylaxis therapy. This has led to outcome improvements such as reduced bleed-related morbidity and mortality, fewer viral infections, and enhanced overall multi-modality care. Most people with haemophilia (PWH) are now able to live normal, active lives. Early diagnosis has improved through increased awareness, physician education, and prenatal diagnosis; while comprehensive care, including state of the art rehabilitation and orthopaedic management for haemophilic arthropathy, eradication therapy for chronic hepatitis C, and better treatments for human immunodeficiency virus, allows PWH to enjoy a better quality of life and improved survival. Efforts are now being made to raise prophylaxis rates through full NHI reimbursement and the use of extended half-life recombinant factor products. Overall, Taiwan has made great strides in haemophilia care and we would like to share these experiences for the benefit of all healthcare providers involved in haemophilia care. Competing Interests: Declaration of competing Interest The authors have no conflicts of interest relevant to this article. (Copyright © 2021. Published by Elsevier B.V.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu